John Lambert Elected Chairman of Mucosis

27-Sep-2010 - Netherlands

Mucosis B.V. announced that John Lambert was elected as member and chair of its Supervisory Board. Having held various key positions at pharmaceutical and biotech companies in both the United States and Europe, Mr. Lambert brings exceptional vaccine industry experience to Mucosis.

From 1998 to 2000 Mr. Lambert was President at Aventis Pasteur MSD, a vaccine joint venture established between Aventis (now sanofi-aventis Group) and Merck & Co, Inc. Subsequently, from 2001 to 2005, he served as President of Chiron Vaccines (now Novartis Vaccines). Mr. Lambert was a non-executive Director at Acambis Plc (U.K.), chairman of the Conseil d’Administration of Farmaprojects S.A. (Spain), non-executive chairman of Cambridge Biostability Ltd. (U.K.) and advisor for Crucell N.V. (Netherlands) on acquisitions and strategy. He is currently Board Director of Novavax Inc. (U.S.A.).

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances